PTD-DBM exhibited promising potential in facilitating hair regrowth. Research suggests the peptide may possibly inhibit loss by regulating this biological pathway. Androgenetic alopecia is considered to have notable physiological and psychological impacts on models affected by it.
The observed phenomenon is a degenerative state exhibiting a distinct configuration of alopecia. The process initiates with the recession of the frontal hairline and alopecia in the vertex or crown region of the skull. The condition advances to result in total alopecia across the frontal and vertex regions of the scalp.
Hair growth undergoes a trichological process consisting of three distinct phases. These phases encompass the anagen phase (a period of active hair growth), the catagen phase (a period of regression and transition), and the telogen phase (a period of hair follicle rest). The overproduction of androgens (specifically testosterone) decreases the anagen phase's length.
The observed phenomenon resulted in decreased hair thickness, accelerated hair replacement, and elevated hair shedding. The anagen phase, which typically spans multiple years, experiences a significant reduction in duration to merely a few months in cases of androgenetic alopecia. The Wnt/β-catenin signaling pathway is of utmost importance among the various cellular pathways that regulate hair growth in hair follicles.
The exocytosis of Wnt proteins triggers the initiation of this signaling pathway. The proteins above exhibit binding affinity towards the Low-Density Lipoprotein-Related Protein (LRP), subsequently inhibiting glycogen synthase kinase-3β (GSK-3β) activity. Glycogen synthase kinase-3 beta (GSK-3β) is an enzymatic protein inhibiting β-catenin activity. Read more on livemint.com